Sinopharm To Restructure Xinjiang Pharmaceutical
This article was originally published in PharmAsia News
Sinopharm has agreed to acquire Xinjiang Pharmaceutical Group, part of State-owned Assets Supervision and Administration Commission of Xinjiang Autonomous Region. Sinopharm plans to strengthen Xinjiang Pharmaceutical into a more competitive drug corporation in Northwest China by pumping in funds as well as providing support such as technology, management and training. With its edge in specialized ethnic medicine, Xinjiang Pharmaceutical accounts for half of the region's pharmaceutical distribution business. Sinopharm has been seeking pharmaceutical firms with good value in its bid to further reinforce its top position in the industry. (Click here for more - Chinese Language)
You may also be interested in...
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.
Market Intel: Why Telehealth, Digital Therapies Will Provide Mental Health Support Beyond COVID-19 Crisis
In this second part of a two-part series focusing on mental health tech, Medtech Insight highlights behavioral digital health companies that have attracted investors’ attention. Part one focused on transcranial magnetic stimulation.